Circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) of patients with glioma had a high concordance with tumor DNA and ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company developing targeted immunotherapies, reported a reduced net los ...

NeOnc Technologies (NTHI) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease Designation, RPDD, to ...

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) shares slid as the Westlake Village, Calif.-based company a clinical-stage medical biotechnology concerm, announced that the U.S. Food and Drug ...

NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare ...

The development of ocular signs of neurofibromatosis type 1 (NF1) is only significant in patients 7 years of age and younger.

Glioblastoma multiforme (GBM), commonly referred to as glioblastoma, is a malignant intracranial tumor derived from glial ...

The University of Cincinnati Cancer Center and other research powerhouses have received a million-dollar grant.

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis. Previous research suggests that platelet-derived growth ...

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis.

(MENAFN- Investor Brand Network) New research shows that firefighters diagnosed with gliomas tend to have a particular set of genetic mutations that aren't so common in individuals engaged in other ...